These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38150061)

  • 1. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
    Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
    J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.
    Avery RA; Mansoor A; Idrees R; Trimboli-Heidler C; Ishikawa H; Packer RJ; Linguraru MG
    Neurology; 2016 Dec; 87(23):2403-2407. PubMed ID: 27815398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.
    Yamasaki F; Takano M; Yonezawa U; Taguchi A; Kolakshyapati M; Okumichi H; Kiuchi Y; Kurisu K
    Childs Nerv Syst; 2020 Mar; 36(3):635-639. PubMed ID: 31701281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
    Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
    Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
    Amato A; Imbimbo BP; Falsini B
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.
    Kilian A; Aigner A; Simon M; Salchow DJ; Potratz C; Thomale UW; Hernáiz Driever P; Tietze A
    J Neurooncol; 2022 Feb; 156(3):589-597. PubMed ID: 34994964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
    Chang L; El-Dairi MA; Frempong TA; Burner EL; Bhatti MT; Young TL; Leigh F
    J AAPOS; 2010 Dec; 14(6):511-7. PubMed ID: 21168074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automatic Visual Acuity Loss Prediction in Children with Optic Pathway Gliomas using Magnetic Resonance Imaging.
    Jiang Z; Parida A; Anwar SM; Tang Y; Roth HR; Fisher MJ; Packer RJ; Avery RA; Linguraru MG
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.
    Rony C; Aharoni S; Halevy A
    Neuropediatrics; 2022 Oct; 53(5):370-375. PubMed ID: 35381604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Role of Conventional and Dynamic Contrast-Enhanced MRI in Optic Pathway Gliomas.
    Jittapiromsak N; Hou P; Liu HL; Sun J; Slopis JM; Chi TL
    J Neuroimaging; 2017 Nov; 27(6):594-601. PubMed ID: 28524459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.
    Boonzaier NR; Hales PW; D'Arco F; Walters BC; Kaur R; Mankad K; Cooper J; Liasis A; Smith V; O'Hare P; Hargrave D; Clark CA
    Neuroimage Clin; 2020; 28():102447. PubMed ID: 33038669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
    Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
    Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
    Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optic pathway glioma and endocrine disorders in patients with and without NF1.
    Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S
    Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
    Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
    J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.
    Thiagalingam S; Flaherty M; Billson F; North K
    Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
    Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
    J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE; Nuding MA
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of chemotherapy on optic pathway gliomas and their sub-components: A volumetric MR analysis study.
    Shofty B; Mauda-Havakuk M; Weizman L; Constantini S; Ben-Bashat D; Dvir R; Pratt LT; Joskowicz L; Kesler A; Yalon M; Ravid L; Ben-Sira L
    Pediatr Blood Cancer; 2015 Aug; 62(8):1353-9. PubMed ID: 25858021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
    Freret ME; Gutmann DH
    J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.